To investigate levels of components of the alternative pathway of complement, and of two activation products, ASP and Bb, in persons ranging in insulin resistance both fasting and following the consumption of a high-fat, low-carbohydrate meal. SUBJECTS: Healthy controls (n ¼ 17) and normoglycaemic first-degree relatives of patients with type II diabetes (n ¼ 15). MEASUREMENTS: All subjects had normal glucose tolerance. Blood was collected for the measurement of plasma glucose, insulin, triglycerides and free fatty acids. Body composition was assessed with dual energy X-ray absorptiometry (DEXA) and whole-body insulin sensitivity with a euglycaemic, hyperinsulinaemic clamp. Basal and postprandial values over 6 h were determined for plasma C3, B, D, Bb and ASP. Basal levels of C1q, C4 and CRP were also determined. RESULTS: Controls did not differ significantly from the relatives of patients with type II diabetes for any metabolic parameter except in their degree of insulin resistance and central fat (kg). Across all subjects, basal levels of C3, but no other complement protein, were correlated with insulin resistance. Native complement proteins, but not ASP or Bb, were correlated with body mass index and the amount (kg) of central fat. Basal levels of C3 and factor B were significantly higher in the relatives group, whereas factor D and the classical pathway proteins C1q and C4 did not differ between the two groups. Postprandially, levels of factor D were significantly reduced in both groups. ASP levels also fell postprandially, the decline achieving significance in the relatives group. CONCLUSIONS: Elevated levels of C3 and factor B in the diabetic relatives group may have resulted from increased synthesis by adipose tissue. There was no evidence of alternative pathway activation in response to a fat meal in terms of ASP or Bb production, or significant consumption of C3 and factor B. These data do not support an essential requirement of the hypothesis that ASP is produced in response to the intake of fat.
Introduction
The Metabolic Syndrome, characterized by insulin resistance, dyslipidaemia, hypertension and central adiposity, carries major risks for premature vascular disease. It is prevalent in several indigenous populations. However, the pathophysiology of its individual components remains controversial. Adipose tissue produces several molecules that are thought to be important in the pathogenesis of insulin resistance, dyslipidaemia and central adiposity. They include leptin, tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), the third component of complement (C3) and its activation byproduct C3a desarg (acylation-stimulating protein, ASP).
1,2 It has been proposed that ASP plays an important role in the regulation of fatty acid uptake and triglyceride formation. 2 Elevated levels of fatty acids are believed to contribute to the development of glucose intolerance by their influence on the supply of excess lipid to muscle and possibly to the pancreatic b cell. 3 Murine fat cells produce all components of the alternative complement pathway required for assembly and control of the C3 converting enzyme, C3b.Bb, 4,5 and in man fat cells produce a number of components of the classical pathway, including C1q and C4. 6 Several studies report elevation of C3 in individuals at risk of arterial disease, including those with hypertension, type II diabetes, dyslipidaemia and coronary artery disease. There is also a correlation between increased C3 concentration and decreased insulin action in Pima Indians. 7 However, the basis for the association between dyslipidaemia and C3 levels is not clear. Prior to its activation, C3 is not known to have biological functions, while its activation leads to structural modifications of the C3 molecule that result in reduced plasma concentration. There is also no evidence that C3 and factors B and D interact significantly (ie to form C3a and subsequently ASP) in the absence of specific activators. Reports of lipid behavior in mice genetically deficient in C3, and hence ASP, have yielded conflicting results. One study showed little effect on lipid metabolism, 8 while some strains have shown effects including a delayed clearance of triglycerides. 9 It is now accepted that in man, plasma ASP levels do not increase in response to a fat meal challenge.
2,10
However, little information is available regarding postprandial changes in other potentially rate-limiting components of the alternative pathway, namely factors B and D.
To clarify these issues, we analyzed levels of components of the alternative pathway in the fasting state and following ingestion of a high fat meal. We also measured levels of ASP and Bb, an activation product of factor B also generated by activation of the alternative pathway. The possibility that elevated C3 levels reflect an acute inflammatory stimulus selective for the alternative pathway was examined by comparison with levels of the classical pathway complement proteins, C1q and C4, and the acute phase inflammatory marker, C-reactive protein (CRP). Two carefully characterized groups of volunteer subjects were studied: (a) healthy control subjects with no family history of diabetes or dyslipidaemia, and (b) normoglycaemic, normolipidaemic first-degree relatives of patients with type II diabetes. The latter are prone to insulin resistance without the confounding effect on lipid metabolism of abnormal levels of glucose.
Subjects and methods

Subjects
Healthy, sedentary, nonsmoking subjects (26 female/6 male subjects), with no history of cardiovascular disease or dyslipidaemia, were included. There were 14 female and three male subjects in the control group and 15 normoglycaemic, normolipidaemic first-degree relatives (12 female/ three male subjects) of diabetic subjects from families with a high incidence of type II diabetes (ie Z2/family). The controls had no family history of type II diabetes. The St Vincent's Hospital Human Research Ethics Committee approved the study and all subjects gave written informed consent. Each subject's weight was stable (o2 kg change) for the previous 3 months. All women were premenopausal, and were not pregnant or lactating at the time of the study.
Protocol
Procedures were undertaken on three separate occasions, each following a 10 h fast. At the first visit, all subjects were shown to have fasting plasma glucose (o6.1 mmol/l) and normal glucose tolerance following a 75 g oral glucose tolerance test. After 7-10 days, blood was collected for the determination of plasma insulin, glucose, triglycerides and free fatty acids. During the same morning, body composition was assessed with dual energy X-ray absorptiometry (DEXA) and a 120 min euglycaemic, hyperinsulinaemic clamp performed to determine whole-body insulin sensitivity. Approximately 1 week later, subjects were given a fat meal and the postprandial response was measured serially over the subsequent 6 h.
Anthropometry and body composition
At 0800 h on the first visit, weight and height were measured in light clothing with footwear removed. Weight was measured to the nearest 0.1 kg using a digital electronic scale. Height was measured to the nearest 0.1 cm using a stadiometer. The body mass index (BMI) BMI was calculated as weight divided by height squared (kg/m 2 ). Whole-body DEXA (Lunar DPX-Lunar Radiation Corporation, Madison, WI, USA software version 1.35 y) was used to analyze body composition according to a three-compartmental model, comprising fat mass, lean tissue and bone mineral content. Measurement of central body fat has been described elsewhere, 11 and includes both visceral and subcutaneous abdominal fat.
Oral glucose tolerance test (OGTT)
Following an overnight fast and after dietary assessment to ensure a carbohydrate intake 4150 g/day over the previous 3 days, glucose tolerance was assessed by a 75 g OGTT. Blood samples for glucose and insulin were taken immediately before and at 30, 60, 90 and 120 min after the glucose load.
Euglycaemic, hyperinsulinaemic clamp
Subjects underwent a 120 min euglycaemic hyperinsulinaemic clamp (insulin dose 50 mU/m 2 /min; Actrapid HM, Novo Industries, Denmark), after a 10 h overnight fast as previously described. 11,12. A variable-rate glucose infusion (25% dextrose) was used to maintain blood glucose levels close to 5 mmol/l. The steady-state glucose infusion rate (GIR; measured over the final 30 min of the clamp) provided an index of whole-body insulin sensitivity.
Oral fat load
Subjects consumed a meal containing B80 g of dietary fat with an energy content of 4250 kJ. 13 Response of complement to an oral fat load PW Peake et al the effect of secreted insulin on postprandial lipids. 13 Subjects remained supine for 1 h prior to and 6 h following the meal. The meal was consumed within 20 min, accompanied by 600 ml water. No other food or beverage was consumed through the testing period. Plasma samples were collected at 0 and 30, 60, 120, 180, 240, 300 and 360 min postprandially.
The meal consisted of cheese (44 g), beef (100 g), fried egg (118 g), copha (coconut oil; 8 g), cracker biscuit (12.5 g), cream (fat 448%) (25 g), strawberries (130 g) and macadamia nuts (20 g); total 458 g.
Biochemical analysis
Plasma glucose was measured by the glucose oxidase method (Yellow Springs Instruments Model 23AM Glucose Analyzer, Yellow Springs, OH, USA). Plasma insulin was measured by radioimmunoassay (Linco RIA Charles, MO, USA). Serum triglycerides and free fatty acid (FFA) concentrations were determined spectrophotometrically using enzymatic colorimetric kits (Roche Diagnostics, Basel, Switzerland and Wako Inc., Japan). Inter-and intra-assay CV were o10% for these assays in our laboratory.
Complement assays
Plasma levels of C1q, C4, C3, B, D, Bb and ASP were measured. ASP was measured by RIA (Amersham), and factor D by in-house sandwich ELISA, using a single vial of pure factor D (Calbiochem) as a standard and antibodies from The Binding Site (UK). Assay CV% was o5%. Bb was measured by commercial Elisa (Quidel, USA). Samples (in EDTA) for measurement of ASP and Bb were separated at 41C within 15 min and snap frozen at À701C. C3 and CRP were quantitated by standard nephelometry (Beckman, Sydney), and C1q, C4 and B by radial immunodiffusion using monospecific polyclonal rabbit antibodies (Dako, Australia) and a Binding Site standard. In these assays, intra-assay CV% was o5% and interassay CV% o15%.
Statistical analysis
Comparisons between groups at baseline or postprandially were performed using one-way ANOVA with Dunnett post tests to compare individual postprandial with fasting values, and paired and unpaired t-tests. Relationships between continuous variables were assessed by simple regression or Pearson correlation analyses as appropriate. Allowance was made for the potentially confounding effect on significance of multiple comparisons by reducing the threshold for acceptance according to the formula 1-0.95 1/n , where n is the number of hypotheses being tested. The CRP levels were not normally distributed, and were compared by the MannWhitney U-test. These analyses were performed using GraphPad Prism. Results are presented as mean7s.e.m.
Results
Subject characteristics
The metabolic characteristics of both groups are shown in Table 1 . Controls did not differ from the relatives group in age or in measures of body composition except for the amount of central fat (kg). As previously described, the latter were significantly more insulin resistant (ie had lower insulin sensitivity, P ¼ 0.01).
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Fasting parameters There were no significant differences in fasting levels of triglycerides, glucose, NEFA or insulin between groups. C3 and factor B were significantly higher in relatives of patients with type II diabetes: levels of C3 in controls and relatives were 1.0870.05 and 1.3770.08 g/l, respectively (P ¼ 0.001), while those for factor B were 210.8715.5 vs 299.9740.9 mg/l, respectively (Po0.05). However, differences between groups were not significantly different for factor D, and the activation by-products Bb and ASP (Figure 2 ). For the two components of the classical pathway, there were also no significant differences between the control and relatives group: levels of C1q were 99.673.5 and 103.275.4 mg/l respectively, while those for C4 were 212.3719.6 and 230.3720.9 mg/l. In this study, the levels of CRP in controls and relatives were low and not significantly different; for controls, the lower 95% CI was 0.7, and the upper 95% CI was 5.3 mg/l. The corresponding values for the relatives group were 0.2 and 5.9 mg/l. The mean values were 2.9 and 2.7 mg/l, respectively.
Correlations between metabolic parameters and complement components across all subjects are shown in Table 2 . Fasting levels of C1q, C4, C3 and factor B in all subjects correlated with BMI and the amount of central fat (kg). Only fasting levels of C3 correlated with the degree of insulin resistance, and no metabolic characteristic correlated with the amount of factor D, or with ASP or Bb. There was no significant correlation between levels of ASP or Bb and those of C3, B or D for both groups.
Fat meal challenge
Postprandial levels of insulin, NEFA and triglycerides, but not plasma glucose, changed significantly after the fat meal Response of complement to an oral fat load PW Peake et al (Figure 1a-d) . Insulin rose up to three-fold 30 min post cibum, and there was a significant difference between groups in the level of insulin at 30 min. There were no significant differences between groups in the response of triglycerides, NEFA or insulin to the fat meal challenge. Postprandially, there were some individual falls in C3 in both groups, but no sustained change over 6 h (Figure 2 ). There was a tendency for factor B to increase over the postprandial period, but this was not significant. However, in both controls and in the relatives group, there was a significant fall in factor D by 30 min post cibum, which was sustained over the period of sampling. ASP fell by a small amount (B20%) from fasting levels in both groups, and this difference achieved significance using the Dunnett post test in the relatives group of patients over a 5 h period. Levels of Bb remained unaltered in both groups (Figure 2 ). Response of complement to an oral fat load PW Peake et al
Discussion
These data show that in subjects with insulin resistance and other features of the Metabolic Syndrome, differences in levels of complement are confined to the alternative pathway. Specifically, levels of C3 and factor B were higher in this group, whereas plasma levels of factor D, C1q and C4 were comparable with controls. It is recognized that complement proteins in the native state exert little, if any, biological influence on the host; such effects are dependent on either physiological or pathological activation via the classical or alternative complement pathways. Several, but not all components exhibit acute phase reactivity and may increase in plasma concentration by up to 50% in the face of an inflammatory stimulus. Possible changes in both complement synthesis and consumption confound attempts to interpret the basis for change in the concentration of a single component. The characteristics of the relatives group were comparable with those in a previous report, which showed that first-degree (male) relatives of patients with type II diabetes tend to be insulin resistant and exhibit postprandial lipid intolerance. 14 The choice of normoglycaemic subjects avoided any secondary effects of elevated plasma glucose on lipid profiles. Previous work makes it clear that C3 is significantly elevated in patients with conditions such as obesity, type II diabetes and dyslipidaemia. Fasting C3 concentrations are significantly raised in Pima Indians, 7 and in familial combined hyperlipidemia (FCHL), 15 while C3 mRNA is raised in the subcutaneous fat of obese subjects. 16 It has been proposed that increased levels of C3 and other inflammatory markers in diabetes result from chronic inflammation induced by 'excess' fat tissue. However, little is known about the behavior of other (potentially ratelimiting) alternative pathway reactants, that is factors B and D, in relation to human adiposity and insulin resistance. These components would be involved during activation of the alternative pathway. Factor B is produced by fat cells, and its concentration is rate limiting in vitro; induction of factor B by TNF-a was associated with a 2-3-fold increase in ASP production by 3T3-L1 cells. 5 Factor D is abundantly expressed in fat, but is rate limiting in the general circulation. Response of complement to an oral fat load PW Peake et al
The concentrations of C3 and B correlated significantly with the degree of adiposity. Both factor B and C3 are acute phase molecules, and there is evidence that excess adipose tissue is associated with the production of proinflammatory molecules. 17 CRP, when bound to C1q may activate the classical pathway, 18 which may therefore also have the potential to change in inflammatory states. However, levels of CRP in the two study groups were comparable, and at the lower end of the normal range. C1q is not an acute phase molecule, whereas C4 exhibits an acute phase response similar in magnitude to that of C3. There were no significant differences between basal levels of C1q and C4 in the two study groups, although mRNA for both of these components has been found in adipose tissue. 6 The explanation for these findings remains unclear. Liver is the site of synthesis of CRP, and it appears unresponsive to certain inflammatory stimuli that induce significant production of C3 by other cell types, such as fibroblasts and macrophages. 19 Hence, one possible explanation for elevated levels of C3 and B is that they reflect increased synthesis in adipose tissue of members of the alternative pathway that are acute phase proteins.
While fat cells produce all components of the alternative complement pathway, 5 there is little evidence that this pathway is activated in patients with the Metabolic Syndrome. Such activation is typically associated with reduction in complement levels and the generation of ASP and Bb. This was not observed in our study. Little is known of the relationship between other components of the alternative pathway and insulin-related abnormalities, except that fasting levels of C3, but not ASP, have been related to insulin action. 7 Our data show significant linkage to insulin resistance for C3 alone among components of the alternative pathway, and no linkage to C1q and C4 levels. The lack of a relationship between insulin resistance and other proteins required for functioning of the alternative pathway argues against C3 being an important correlate or antecedent of this condition. Correlations between levels of C3 and C4 and fat distribution have been previously reported, 6 but the disassociation between levels of factor D, which is produced predominantly by fat tissue, and several measures of body composition is notable. Factor D is not an acute phase protein, 20 and its level was not significantly raised in the relatives group, a result consistent with previous data in all but the morbidly obese. 21, 22 We found no significant change in C3 and B in either group following a fat meal. While a postprandial rise in C3 has been reported in subjects with FCHL as well as healthy controls, 23 other groups (including our own) have failed to observe significant change in either of these complement components. 10, 16 Levels of factor D fell significantly following ingestion of the fat meal, and levels of ASP fell by B20% in both subject groups, although only the fall in the relatives group attained statistical significance. These early changes were suggestive of vascular redistribution, possibly associated with increased blood supply to adipose tissue, 24 rather than a change in synthesis or catabolism. The low molecular weights of factor D and ASP (24 000 and 9 000 kDa, respectively) suggest that these molecules would be more susceptible to redistribution than either native C3 or factor B (185 000 and 93 000 kDa, respectively). Metabolic studies in vivo have shown that C3-derived breakdown products equilibrate rapidly between the intravascular and extravascular compartments. 25 Proposed links between C3 and lipid metabolism depend on mechanisms that include the production of ASP and deposition of C3 in atherosclerotic lesions. The ASP hypothesis postulates that chylomicrons act as a catalyst to produce ASP in the capillary via the alternative pathway of complement. However, reports of lipid behavior in mice genetically deficient in C3, and hence ASP, have yielded conflicting results. One study showed little effect on lipid metabolism, 8 while others have shown effects including reduced body weight and, in some strains, delayed clearance of triglycerides postprandially. 9 It is now accepted that in man, plasma ASP levels do not increase in vivo in response to a fat meal challenge, 2, 10 and in this study levels in the relatives group fell over the postprandial period. Production of ASP across subcutaneous adipose tissue postprandially has been examined by comparison of arterial and venous sampling. 26 However, the raw data showed no significant increases in ASP, and levels were abnormally high, being greater in basal samples than those commonly seen in complement activating diseases such as systemic lupus erythematosus. 27 By contrast, arteriovenous and open-flow microperfusion studies of adipose tissue have been able to detect significant increases post cibum in IL-6 levels, and such changes were reflected in the general circulation. [28] [29] [30] Our measurements of Bb provided an independent measure of complement activation to that offered by ASP, and these data showed no significant alteration. Bb is produced upon activation of factor B, and is an obligate component of the alternative pathway convertase responsible for the production of ASP from C3. A possible explanation for the failure to detect increased levels of ASP postprandially is that significant quantities may be sequestered by adipose tissue. However, levels of Bb did not rise postprandially. Bb plays no known role in fat metabolism, and a receptor has not been described. It would therefore be unlikely to be sequestered by adipose tissue.
In summary, we have examined the behavior of the alternative pathway of complement in response to a fat meal challenge. Postprandially, plasma levels of C3 and factor B remain generally unchanged, while levels of factor D decreased. In addition, levels of activation products of the alternative pathway of complement during this period either did not change (Bb) or significantly decreased (ASP). We conclude that there is no evidence of complement activation postprandially, contradicting a key requirement of the hypothesis that ASP generation plays a significant role in the postprandial handling of triglycerides and fatty acids. Our data also suggest that the association between levels of C3 and factor B and increased obesity may result from
Response of complement to an oral fat load PW Peake et al synthesis of these proteins by adipose tissue, but do not necessarily reflect a causal linkage.
